Technical Analysis for ZYME - Zymeworks Inc

Grade Last Price % Change Price Change
grade B 33.1 -2.90% -0.990
ZYME closed down 2.9 percent on Tuesday, October 1, 2019, on 77 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ZYME trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -2.90%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.90%
Pocket Pivot Bullish Swing Setup -2.90%
Fell Below 20 DMA Bearish -1.75%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.75%

Older signals for ZYME ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Companies Cancer Biopharmaceutical Antibodies Treatment Of Cancer Life Sciences New Jersey
Is ZYME a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 39.1
52 Week Low 14.34
Average Volume 6,990
200-Day Moving Average 25.5739
50-Day Moving Average 33.601
20-Day Moving Average 35.2055
10-Day Moving Average 34.717
Average True Range 1.5378
ADX 22.16
+DI 22.2221
-DI 23.6262
Chandelier Exit (Long, 3 ATRs ) 34.4866
Chandelier Exit (Short, 3 ATRs ) 37.3834
Upper Bollinger Band 38.1253
Lower Bollinger Band 32.2857
Percent B (%b) 0.14
BandWidth 16.587181
MACD Line 0.1266
MACD Signal Line 0.4464
MACD Histogram -0.3198
Fundamentals Value
Market Cap 825.51 Million
Num Shares 24.9 Million
EPS -3.52
Price-to-Earnings (P/E) Ratio -9.40
Price-to-Sales 24.35
Price-to-Book 15.67
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.240
Resistance 3 (R3) 34.257 33.893 34.050
Resistance 2 (R2) 33.893 33.603 33.885 33.987
Resistance 1 (R1) 33.497 33.424 33.695 33.480 33.923
Pivot Point 33.133 33.133 33.233 33.125 33.133
Support 1 (S1) 32.737 32.843 32.935 32.720 32.277
Support 2 (S2) 32.373 32.664 32.365 32.213
Support 3 (S3) 31.977 32.373 32.150
Support 4 (S4) 31.960